This test was developed and its performance characteristics determined by Marshfield Labs. This laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) to perform high complexity testing.
This test is designed to support medical, not forensic, purposes. The detection of drugs listed in this survey is to be used for compliance monitoring and identification of abuse.
This test uses immunoassy methods to first screen for the following drug classes or method groups: amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, ethanol, methadone, opiate method group, oxycodone method group, and buprenorphine at and above cut-off levels.
If the screen is positive, this test also includes mass-spectrometry method confirmation. Also includes specimen validity testing (creatinine, pH, and oxidants) to detect adulteration, dilution, or substitution of the specimen.
All confirmations / quantitations are charged separately as needed.
The amphetamine class includes phentermine, amphetamine, methamphetamine, ephedrine, pseudoephedrine, MDA, MDEA, and MDMA (Ecstasy).
Barbiturates class includes butalbital, amobarbital, secobarbital, pentobarbital, and phenobarbital.
Benzodiazepines class includes desalkylflurazepam, nordiazepam, 7-aminoflunitrazepam, oxazepam, temazepam, 7-aminoclonazepam, lorazepam, alpha-hydroxyalprazolam, and diazepam.
The methadone method group includes parent methadone and EDDP (methadone metabolite)
Opiate method group includes morphine, codeine, hydrocodone, hydromorphone.
Oxycodone method group includes oxycodone and oxymorphone.
Buprenorphine method group includes buprenorphone and norbuprenorphine.
The immunoassay screening test for the Benzodiazepines drug class does not detect Lorazepam or Clonazepam well. If either of these drugs are suspected, please order the test “Benzodiazepines, Urine, Confirm Only by LC/MSMS” in addition to this test to insure detection if present.